


LISTING OF CLAIMS:

The following is a listing of claims with claims 3, 9 and 12 shown as amended:

1) In the Claims:

Claims 1-2 (canceled).

3. (currently amended): A compound represented by the following formula (II), and the pharmaceutically acceptable salt thereof:



(II)

wherein

$R_1, R_2$  is a straight or branched lower alkyl or alkoxy group having 1 to 6 carbon atoms, a polyethyleneglycol group selected from the group consisting of an ethyl group, a propyl group, an ethyleneglycol group, diethyleneglycol group, triethyleneglycol group, tetraethyleneglycol group, hexaethyleneglycol group, heptaethyleneglycol group or a methoxyethyleneglycol group; and

R<sub>2</sub> is a straight or branched lower alkyl or alkoxy group having 1 to 6 carbon atoms, a polyethyleneglycol group selected from the group consisting of an ethyl group, a propyl group, an ethyleneglycol group, diethyleneglycol group, triethyleneglycol group, tetraethyleneglycol group, hexaethyleneglycol group, heptaethyleneglycol group or a methoxyethyleneglycol group, which can be chelating with transition metal ion comprising Ni metal ion.

Claims 4-8 (canceled).

9. (currently amended): A pharmaceutical composition comprising the compounds of formula (II) (1) to (VII) as set forth in claim 3 4 or pharmaceutically acceptable salt thereof as an active ingredient together with a pharmaceutically acceptable carrier to treat or prevent various breast cancers by way of reproducing singlet state oxygen radical and superior cell cytotoxic activity.

Claims 10-11 (canceled).

12. (currently amended): A method of treating or preventing various breast cancers such as stomach cancer, liver cancer, lung cancer, cervical cancer in human or mammal, wherein the method comprises administering a therapeutically effective amount of the compound of formula of (II) (1) to (VII) as set forth in claim 3 4 or pharmaceutically acceptable salt thereof.

Claims 13-48 (canceled).